



Contact:
Colleen Ward
Office: 314.880.8873
Cell: 314.623.0450
cward@biostl.org

BioGenerator Announces Investment in Cardialen

ST. LOUIS – March 19, 2015 – [BioGenerator](#), an evergreen investor that creates, grows and invests in promising companies and entrepreneurs, announced the closing of a post-seed, follow on financing in Cardialen, Inc., a medical device company developing a new therapy for the treatment of atrial fibrillation (AF) based on research that originated from the laboratory of Professor Igor Efimov, a scientist at Washington University in St. Louis.

AF is the most common sustained cardiac arrhythmia, affecting nearly 9 million people in the U.S. and Europe. Current treatments for AF range from drug treatments and external cardioversion to catheter ablation surgery, all of which have limited efficacy and significant side effects. Cardialen's solution will deliver a novel series of low energy electrical pulses via a small implantable device that will not cause pain or tissue damage and will have the capability to adapt to an individual patient's arrhythmia.

"Cardialen has developed highly promising technology that will provide an innovative therapy for AF patients," said Eric Gulve, Ph.D., president of BioGenerator. "BioGenerator is one of the original investors in Cardialen, and the current financing represents our fourth investment in the company. We believe the company's technology has the potential to provide substantial clinical benefit to patients suffering from refractory paroxysmal and persistent AF."

Other investors in this round of funding include Cultivation Capital Life Sciences, St. Louis Arch Angels, Twin Cities Angels, BELLE Capital, Heartland Angels, Lambda Fund Management, and private individuals. The investment will enable Cardialen to continue to advance their technology in human clinical studies.

Cardialen is led by Paula Skjefte, a medical device executive who brings over 30 years of medical device industry experience, including a major portion as VP of cardiac device leadership at Medtronic. "We at Cardialen are excited to move forward with this breakthrough therapy," said Skjefte. "There is a great need for a new treatment for AF and we believe our solution will reduce symptoms, hospitalizations and healthcare costs for these patients. This round of investment from BioGenerator and our other investors will allow us to continue our work and move closer to providing a viable, long term solution for the treatment of AF."

Cardialen received its initial investment from BioGenerator, the Twin Cities Angels and the St. Louis Arch Angels in 2009. BioGenerator has invested a total of \$580,000 into Cardialen in four financings. BioGenerator's portfolio includes several promising medical device companies, including Cardialen, SynerZ Medical, Pulse Therapeutics and MediBeacon. In 2014, BioGenerator invested \$700,000 in medical device companies alone.

About BioGenerator

BioGenerator produces a sustained pipeline of successful bioscience companies and entrepreneurs in St. Louis by creating, growing and investing in promising new enterprises. BioGenerator is a nonprofit subsidiary of BioSTL, which advances St. Louis' prosperity by cultivating a thriving bioscience sector, building regional capacity to capitalize on St. Louis' world class medical and plant biosciences. Please visit www.BioGenerator.org for additional information. Follow BioGenerator on Twitter [@BioGeneratorSTL](https://twitter.com/BioGeneratorSTL).

###